Association of circulating preptin with non-alcoholic fatty liver disease: A case-control study



Preptin, Hepatosteatosis, Non-alcoholic fatty liver disease


Background/Aim: Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of metabolic disorders and identifying patients with a high risk of fibrosis is crucial. A scoring system, the FIB-4 score, based on clinical and biochemical parameters was developed to predict fibrosis. NAFLD is associated with various peptide hormones. However, the relationship of preptin, a newly discovered peptide critical for regulating energy metabolism, with NAFLD remains unclear. Therefore, we aimed to determine the relationship of preptin with NAFLD and evaluate whether there was an association between serum preptin levels and FIB-4 score. Methods: In this prospective study, serum biochemical parameters and serum preptin levels of 51 patients with grade 2-3 hepatosteatosis proven by ultrasonography and 35 healthy controls with similar demographic characteristics were compared. Serum preptin levels were measured using ELISA. The FIB-4 scores were calculated and recorded. Results: The serum preptin levels were higher in the NAFLD group than in the control cases (P<0.001). Among the patients, the sensitivity, specificity, positive predictive, and negative predictive values of preptin above a cut-off value of ≥62.3 were 85.7%, 56.9%, 85.3%, and 57.7%, respectively, with an accuracy of 68.6%. The preptin level was negatively correlated with the FIB-4 score and AST in the patient group (P=0.004 and P=0.014, respectively). The linear regression model revealed that there was a significant relationship between the FIB-4 score and preptin (P<0.05). Each 1 unit increase in the FIB-4 score induced a decrease of 86.37 units in preptin values (R²=%8.5). Conclusion: We demonstrated that the serum preptin levels were higher in patients with NAFLD than healthy individuals and negatively correlated with the FIB-4 score and AST levels. Preptin may have a role in the pathogenesis of NAFLD, is likely to distinguish patients with mild and severe liver damage and may be a useful marker in predicting a high risk for progression to fibrosis. Further studies establishing a stratification system including plasma preptin level and the FIB-4 score and its verification with liver biopsies are required.


Download data is not yet available.


Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20:9330-7.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.

Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016;65:1017-25.

Mishra A, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2012;2:135-44.

Mallet V, Parlati L, Vallet-Pichard A, Terris B, Tsochatzis E, Sogni P, et al. FIB-4 index to rule-out advanced liver fibrosis in NAFLD patients. Presse Med. 2019;48:1484-88.

Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int J Mol Sci. 2017;29:1649.

Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, et al. Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease. Med Princ Pract. 2019;28:463-9.

Dallio M, Masarone M, Caprio GG, Sarno RD, Tuccillo C, Sasso FC, et al. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. J Gastrointestin Liver Dis. 2017;26:261-268.

Cornish J, Callon KE, Bava U, Watson M, Xu X, Lin JM, et al. Preptin, another peptide product of the pancreatic β-cell, is osteogenic in vitro and in vivo. Am J Physiol Endocrinol Metab. 2007;292:117-22.

Buchanan CM, Philips AR, Cooper GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J. 2001;360:431-9.

Aydın S, Celik O, Gurates B, Sahin I, Ulas M, Yilmaz M, et al. Concentrations of preptin, salusins and hepcidins in plasma milk of lactating women with or without gestational diabetes mellitus. Peptides 2013;49:123-30.

Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides. 2014;56:94-110.

Aslan M, Celik O, Karsavuran N, Celik N, Dogan DG, Botan E, et al. Maternal serum and cord blood preptin levels in gestational diabetes mellitus. J Perinatol. 2011;31:350–5.

Celik O, Celik N, Hascalik S, Sahin I, Aydin S, Ozerol E. An appraisal of serum preptin levels in PCOS. Fertil Steril. 2011;95:314–16.

Mierzwicka A, Kuliczkowska-Plaksej J, Kolačkov K, Bolanowski M. Preptin in women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34:470-475.

Yang G, Li L, Chen W, Liu H, Boden G, Li K. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Ann Med. 2009;41:52–6.

Abd El Dayem SM, Battah AA, El Shehaby A, Allah NA. Assessment of human cartilage glycoprotein 39 (YKL-40), preptin, and nitric oxide in adolescent patients with type 1 diabetes and its relation to cardiorenal affection. J Pediatr Endocrinol Metab. 2015;28:309-14.

Cai H, Liu Q, Dong X, Cai Y, Yao J, Liu Y. Plasma preptin levels are decreased in patients with essential hypertension. Pharmazie 2018;73:274-8.

Ozkan Y, Timurkan ES, Aydın S, Sahin I, Timurkan M, Citil C, et al. Acylated and desacylated ghrelin, preptin, leptin, and nesfatin-I peptide changes related to the body mass index. Int J Endocrinol. 2013;2013:1-7.

Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014;9:134-40.

Doğan FB, Cicek D, Aydın S, Dertlioglu SB, Halisdemir N, Ucak H, et al. Serum preptin and amylin values in psoriasis vulgaris and Behçet's patients. J Clin Lab Anal. 2016;30:165-8.

Wang H, Gao B, Wu Z, Wang H, Dong M. Alteration of serum adropin level in preeclampsia. Pregnancy Hypertens. 2017;8:6-8.

Wang R, Xue A, Zheng W, Wang L, Yan F, Hu W, et al. Elevated serum preptin concentrations in patients with diabetic nephropathy. J Investig Med. 2019;67:1048-52.

Glück M, Glück J, Wiewióra M, Rogala B, Piecuch J. Serum irisin, adropin, and preptin in obese patients 6 months after bariatric surgery. Obes Surg. 2019;29:3334-41.






Research Article

How to Cite

Arğun D, Basim P, Börkü Uysal B, Argun F. Association of circulating preptin with non-alcoholic fatty liver disease: A case-control study. J Surg Med [Internet]. 2021 Jun. 1 [cited 2024 Jun. 14];5(6):628-32. Available from: